AC
CLVS

Armistice Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Armistice Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,256,000
Closed -$10.8M – 144
2020
Q4 		$10.8M Buy
2,256,000
+408,000
+22% +$2.06M 0.37% 68
2020
Q3 		$10.8M Buy
1,848,000
+248,000
+16% +$1.48M 0.39% 62
2020
Q2 		$10.8M Buy
+1,600,000
New +$12.1M 0.47% 60
2019
Q2 		– Sell
-2,100,000
Closed -$37.9M – 85
2019
Q1 		$52.1M Sell
2,100,000
-2,936,000
-58% -$73.6M 2.85% 7
2018
Q4 		$90.4M Buy
5,036,000
+3,400,000
+208% +$69.5M 6.86% 2
2018
Q3 		$48M Buy
1,636,000
+1,012,000
+162% +$39.2M 2.88% 8
2018
Q2 		$28.4M Buy
624,000
+156,000
+33% +$7.59M 1.85% 20
2018
Q1 		$24.7M Buy
+468,000
New +$27.3M 1.89% 23

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Armistice Capital's CLVS Position: Q1 2021 in Review

Armistice Capital sold out of Clovis Oncology, Inc. (CLVS) in Q1 2021, closing a stake of 2,256,000 shares — an estimated $10.8M sold.

Armistice Capital first reported a position in CLVS in Q1 2018 and held it in 8 quarters. The position peaked at $90.4M in Q4 2018. 165 funds tracked by Wall St. Rank hold CLVS as of Q1 2021.

  • Armistice Capital reported no remaining Clovis Oncology, Inc. position as of Q1 2021 after selling out during the quarter.
  • Armistice Capital sold 2,256,000 Clovis Oncology, Inc. shares in Q1 2021, an estimated $10.8M.
  • Armistice Capital first reported a position in Clovis Oncology, Inc. in Q1 2018 and held it in 8 quarters.
  • Armistice Capital's Clovis Oncology, Inc. position peaked at $90.4M in Q4 2018.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2021.

Based on Armistice Capital's 13F filing for Q1 2021, filed 17 May 2021.